The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

PhRMA said in a January submission to the US trade review that US companies were the “constant target of compulsory licensing ...

HIV and global health activists say the deployment of Gilead’s twice-a-year HIV prevention shot is the world’s best chance to beat back the virus and prevent new infections.

Explore how India's 20-year product patent regime transformed its pharma industry from generics to innovation, the economic impact, and future challenges in drug discovery and IP battles.

Russian drugmaker Geropharm has received a compulsory license from the Russian state to produce a generic of Ozempic (semaglutide) developed by Denmark’s Novo Nordisk (NOV: N). As in case of Ozempic, ...

Potential US tariffs add urgency to the EU’s pharma regulation debate, balancing industry calls for innovation against concerns over medicine shortages and patient care.

Specifically, the authors investigated the impact of the 2001 Doha Declaration on trends in compulsory licensing of pharmaceuticals. They highlight the need for further systematic evaluation of global ...

This arrangement often gives the patent holder a market monopoly and the power to ask any price it chooses. Voluntary licensing and compulsory licensing/government use are two approaches to increase ...

A decade ago, access to medicines was a different story. Governments were willing to use compulsory licensing to produce generic versions of drugs without approval from the patent holders. Meanwhile, ...

On Oct 2, 2024, pharmaceutical firm Gilead announced that it had issued six royalty-free, voluntary licenses to produce generic lenacapavir for distribution within 120 countries with a high HIV burden ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.